The epithelial-mesenchymal transition (EMT) is a key driver of tumor malignancy and cancer progression. EMT converts epithelial cells into mesenchymal cells and is linked to the acquisition of stem-like properties, which are crucial for cancer initiation and propagation. EMT is a natural transdifferentiation program that occurs during development and tissue repair, enabling cells to switch between epithelial and mesenchymal states. This plasticity allows cells to adapt to changing environments and is essential for processes like wound healing and tumor progression. In cancer, EMT is co-opted by tumor cells to gain traits associated with high-grade malignancy, such as motility and invasiveness. EMT also plays a role in generating cancer stem cells (CSCs), which are responsible for tumor recurrence and resistance to therapy. The EMT program is regulated by various transcription factors and is involved in the maintenance of stem-like states in both normal and neoplastic tissues. Recent studies suggest that EMT is not a binary switch but a dynamic process that allows cells to retain some epithelial characteristics while acquiring mesenchymal traits. The EMT program is also linked to the development of CSCs, which can be influenced by EMT-TFs such as Slug and Snail. EMT is activated by various signals, including growth factors and cytokines, and is essential for tumor progression and metastasis. The EMT program is also involved in the invasion-metastasis cascade, where carcinoma cells acquire the ability to invade, circulate, and form metastases. However, the final step of colonization, where cancer cells establish themselves in distant tissues, is not directly controlled by EMT. Instead, it requires adaptation to new environments, which may involve other mechanisms. The EMT program is a central regulator of cancer progression, and its activation can enhance tumor-initiation and metastatic potential. Understanding the mechanisms of EMT and its regulation is crucial for developing new therapeutic strategies to treat advanced carcinomas.The epithelial-mesenchymal transition (EMT) is a key driver of tumor malignancy and cancer progression. EMT converts epithelial cells into mesenchymal cells and is linked to the acquisition of stem-like properties, which are crucial for cancer initiation and propagation. EMT is a natural transdifferentiation program that occurs during development and tissue repair, enabling cells to switch between epithelial and mesenchymal states. This plasticity allows cells to adapt to changing environments and is essential for processes like wound healing and tumor progression. In cancer, EMT is co-opted by tumor cells to gain traits associated with high-grade malignancy, such as motility and invasiveness. EMT also plays a role in generating cancer stem cells (CSCs), which are responsible for tumor recurrence and resistance to therapy. The EMT program is regulated by various transcription factors and is involved in the maintenance of stem-like states in both normal and neoplastic tissues. Recent studies suggest that EMT is not a binary switch but a dynamic process that allows cells to retain some epithelial characteristics while acquiring mesenchymal traits. The EMT program is also linked to the development of CSCs, which can be influenced by EMT-TFs such as Slug and Snail. EMT is activated by various signals, including growth factors and cytokines, and is essential for tumor progression and metastasis. The EMT program is also involved in the invasion-metastasis cascade, where carcinoma cells acquire the ability to invade, circulate, and form metastases. However, the final step of colonization, where cancer cells establish themselves in distant tissues, is not directly controlled by EMT. Instead, it requires adaptation to new environments, which may involve other mechanisms. The EMT program is a central regulator of cancer progression, and its activation can enhance tumor-initiation and metastatic potential. Understanding the mechanisms of EMT and its regulation is crucial for developing new therapeutic strategies to treat advanced carcinomas.